What do systematic reviews say?

Summary of findings: Non‐intensive vs intensive follow‐up

Summary of findings: Non‐intensive showed no clear difference in overall survival compared with intensive follow‐up (high certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 0.98 [0.84, 1.15]
  2 studies · 2563 participants
  High

Summary of findings: Non‐intensive vs intensive follow‐up

Summary of findings: Non‐intensive showed no clear difference in disease‐free survival compared with intensive follow‐up (low certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 0.84 [0.71, 1]
  2 studies · 2563 participants
  Low

Summary of findings: Non‐intensive vs intensive follow‐up

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 639 participants
  High

Summary of findings: Decentralised vs centralised follow‐up

Summary of findings: Decentralised showed no clear difference in overall survival compared with centralised follow‐up (moderate certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 1.07 [0.64, 1.78]
  1 study · 968 participants
  Moderate

Summary of findings: Decentralised vs centralised follow‐up

Summary of findings: Decentralised showed no clear difference in disease‐free survival compared with centralised follow‐up (moderate certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 1.06 [0.76, 1.47]
  2 studies · 1264 participants
  Moderate

Summary of findings: Decentralised vs centralised follow‐up

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 356 participants
  High

Summary of Findings Table ‐ PBI?APBI vs WBRT

Summary of Findings Table ‐ PBI?APBI probably leads to higher local recurrence‐free survival ‐ total (LR‐FS) compared with WBRT (moderate certainty).

• Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
  HR 1.21 [1.03, 1.42]
  8 studies · 13168 participants
  Moderate

Summary of Findings Table ‐ PBI?APBI vs WBRT

Summary of Findings Table ‐ PBI?APBI probably leads to higher cosmesis, physician/nurse‐reported compared with WBRT (moderate certainty).

• Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
  OR 1.57 [1.31, 1.87]
  6 studies · 3652 participants
  Moderate

Summary of Findings Table ‐ PBI?APBI vs WBRT

Summary of Findings Table ‐ PBI?APBI showed no clear difference in overall survival compared with WBRT (high certainty).

• Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
  HR 0.99 [0.88, 1.12]
  8 studies · 13175 participants
  High

Summary of Findings Table ‐ PBI?APBI vs WBRT

Summary of Findings Table ‐ PBI?APBI probably leads to higher subcutaneous fibrosis (late RT toxicity) compared with WBRT (moderate certainty).

• Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
  OR 5.07 [3.81, 6.74]
  2 studies · 3011 participants
  Moderate

Summary of Findings Table ‐ PBI?APBI vs WBRT

Summary of Findings Table ‐ PBI?APBI showed no clear difference in cause‐specific survival (C‐SS) compared with WBRT (moderate certainty).

• Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
  HR 1.06 [0.83, 1.36]
  7 studies · 9865 participants
  Moderate

Summary of Findings Table ‐ PBI?APBI vs WBRT

Summary of Findings Table ‐ PBI?APBI showed no clear difference in distant metastasis‐free survival (DM‐FS) compared with WBRT (moderate certainty).

• Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
  HR 0.95 [0.8, 1.13]
  7 studies · 11033 participants
  Moderate

Summary of Findings Table ‐ PBI?APBI vs WBRT

Summary of Findings Table ‐ PBI?APBI showed no clear difference in subsequent mastectomy compared with WBRT (high certainty).

• Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
  OR 0.98 [0.78, 1.23]
  3 studies · 3740 participants
  High

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1250 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.37, 3.17]
  1 study · 137 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Very low